New hope for tough blood cancer: early trial tests experimental drug
NCT ID NCT07454187
Summary
This early-stage study is testing a new drug called SG2918 in patients whose multiple myeloma has returned or stopped responding to other treatments. The main goal is to check if the drug is safe and what side effects it causes in about 40 participants. Researchers will also look for early signs that the drug might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
The First Affiliated Hospital Of Soochow University
Suzhou, Jiangsu, 215006, China
Contact Email: •••••@•••••
-
The Second Affiliated Hospital Of Xi an Jiaotong University (Xibei Hospital)
Xi’an, Shanxi, 710000, China
Contact Email: •••••@•••••
-
The Second Affiliated Hospital Zhejiang University School Of Medicine
Hangzhou, Zhejiang, 310056, China
Conditions
Explore the condition pages connected to this study.